Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 11,528 |
|
|||||
| News | - | ||||||
| Day High | 0.47 | Low High |
|||||
| Day Low | 0.462 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| BioVie Inc | BIVI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.462 | 09:35:05 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.47 | 0.462 | 0.47 | 0.462 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 80 | 11,528 | $ 0.4682817 | $ 5,398 | - | 0.405 - 6.31 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:34:50 | 100 | $ 0.462 | USD |
BioVie Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 18.34M | 39.87M | - | 0 | -50.26M | -1.26 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
BioVie News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIVI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.46 | 0.4998 | 0.44 | 0.4797414 | 446,833 | 0.002 | 0.43% |
| 1 Month | 0.4803 | 0.4998 | 0.405 | 0.4668017 | 518,289 | -0.0183 | -3.81% |
| 3 Months | 0.5669 | 0.5698 | 0.405 | 0.4894922 | 626,060 | -0.1049 | -18.50% |
| 6 Months | 1.42 | 3.31 | 0.405 | 1.31 | 1,518,649 | -0.958 | -67.46% |
| 1 Year | 5.41 | 6.31 | 0.405 | 1.81 | 1,004,489 | -4.95 | -91.46% |
| 3 Years | 17.24 | 17.9006 | 0.405 | 3.55 | 525,446 | -16.78 | -97.32% |
| 5 Years | 10.50 | 46.0977 | 0.405 | 4.16 | 436,116 | -10.04 | -95.60% |
BioVie Description
| BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. |
